Latest news
Loading news…
argenx
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Boston, Massachusetts, United States Founded 2008 1001-5000 employees For Profit
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
argenx on Acquirezy — acquisitions, funding rounds, investments, investors, key people & contacts.
Total Funding
$3.05B
Funding Rounds
9
Last Funding
Acquisitions
1
Investments
4
1 exits
Monthly Visits
Contacts
832
Ticker
ARGX
EBR - Euronext Brussels
Patents
10
1 trademarks
About argenx
Funding & Financials
- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Public
- Ticker
- ARGX
- Exchange
- EBR - Euronext Brussels
- IPO date
- Jul 10, 2014
- Raised at IPO
- $56.86M
- Valuation at IPO
- $179.11M
Web Traffic
- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 12
- Active products
- 18
- Patents granted
- 10
- Trademarks
- 1
- Top patent class
- Organic Chemistry
- IT spend
- $55.99M
Investor Activity
- Investments
- 4
- Lead investments
- 3
- Portfolio orgs
- 3
- Exits
- 1
- Exits via IPO
- 1
Company Info
- Founded
- 2008
- Employees
- 1001-5000
- Operating status
- Active
- Company type
- For Profit
- Org types
- company, investor
- Founders
- 1
- News articles
- 540
- HQ
- Boston, Massachusetts, United States
- Region
- Greater Boston Area, East Coast, New England
- Exit date
- Jul 10, 2014
Signals & Scores
- Heat score
- High
- Growth score
- Low
- Trend (7d)
- -0.2
- Trend (30d)
- -1.1
- Trend (90d)
- -0.3
- Last leadership hire
- May 6, 2026
argenx Funding Rounds
9 results
Upgrade to Pro to view this datasetUpgrade
| Organization Name | Funding Type | Lead Investor Names | Org Hq Country | ||
|---|---|---|---|---|---|
1–5 of 9Show
Page 1 / 2
argenx Investments
Loading columns…
0 of 0Show
Page 1 / 1
argenx Acquisitions
2 results
| Acquiree Name | Acquirer Name | Acquiree Industries | Acquiree Hq Country | ||
|---|---|---|---|---|---|
| Forte Biosciences | $2.2B | 2026-07-27 | argenx | BiotechnologyHealth CareLife SciencePharmaceutical | United States |
| Food and Drug Administration - Priority Review Voucher | $102M | 2020-11-23 | argenx | — | — |
1–2 of 2Show
Page 1 / 1
argenx Key People
Research Fellow
Non-executive Director
Associate Director Regulatory Affairs Labeling
CFO
Chief Executive Officer
Director Discovery
CSO
832
professional contacts at argenx
Contact execs at argenx →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Bulk Dataset Export
Need the data in bulk? Buy the entire dataset.
5.4M company profiles200K+ acquisitions700K+ funding rounds327K investors2M+ people61M contacts45K schools
Delivered as CSV, JSON or Parquet — at startup-friendly pricing.
Recent News related to argenx
Loading news…
FAQs about argenx
People who checked this page also checked these
Sectors argenx invests & acquires in
Browse the full Acquirezy directory.